SOURCE: XenaCare Holdings, Inc.

XenaCare Holdings, Inc.

October 05, 2010 08:21 ET

XenaCare Announces Entry Into the 51 Billion Dollar Pet Product Market With the Acquisition of EstraPet™

BOCA RATON, FL--(Marketwire - October 5, 2010) -  XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the branding, marketing and retail distribution of consumer healthcare products, announced today its entry into the 51 Billion dollar pet needs marketplace. The Company acquired all rights to the natural hormone modulator pet product, EstraPet™, including its trademark, pending patent application and the web domain

Frank Rizzo, CEO of XenaCare, commented, "We believe that this is a product which has substantial market potential which we hope to realize by utilizing some of the same marketing and advertising techniques we developed for our Cobroxin product. EstraPet™ should be well accepted in the pet industry because the product meets the need for a natural hormone modulator. It is the only known one on the market today."

Like all mammals, animals lose sex hormones either gradually through aging or abruptly, through spaying or neutering. These animals are at far greater risk for various health problems such as:

  • Bone and Muscles Loss
  • Cardiovascular and Periodontal Problems
  • Cancer
  • Weight Control
  • Loss of Brain and Bladder Function
  • Ligament Strength

Of the 93.6 million cat and 77.5 million dog pets, 75% are spayed or neutered. 45.5 Billion dollars was spent on pets in 2009. (Information from Ownership statistics are gathered from APPA's 2009 National pet owner Survey.) EstraPet™ can support spaying or neutering without the above unintended physiologic consequences from sex hormone loss.

Cautionary Note Concerning Forward-Looking Statements
Except for the historical and present factual information contained herein, the matters set forth . Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company's current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at

Contact Information

  • Contact:
    XenaCare Holdings, Inc.
    Frank Rizzo
    Email Contact